Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective. Erivedge (vismodegib) was made available to patients with advanced basal cell carcinoma (BCC) unable to receive surgery or radiotherapy via the old CDF in 2013.
Pharmatimes